Numerous animal studies and human clinical trials have demonstrated the potential of cytokines as cancer immunotherapeutics. However, due to heterogeneity of human cancers, each cytokine is likely to cure only limited types of cancers. A novel cytokine, IFN-gamma-inducing factor (IGIF), has recently been cloned and shown to strongly induce IFN- gamma production, stimulate T cell proliferation and augment NK cell activity in vitro. The immunological characteristics of IGIF are strikingly reminiscent of IL-12, the most potent antitumor cytokine identified yet. Since the antitumor effects of IL-12 are largely dependent on IFN-gamma induction, and since IGIF induces more IFN- gamma than IL-12, it is possible that IGIF is also a potent antitumor agent, either on its own or in combination with other cytokines. We have recently demonstrated that IGIF induces IFN-gamma production in vivo, up-regulates MHC class I expression in Renca tumor cells in vitro, and elicits long-term antitumor immunity against Renca and K1735 tumors in vivo. In this application, we propose to explore the potential of IGIF as a cancer immunotherapeutic.
In Specific Aim 1, we will generate reagents including IGIF antisera, IGIF-high expression vectors and tumor cell transfectants, which are necessary for the IGIF studies proposed here. To determine the mechanisms through which IGIF exerts its antitumor effects, Specific Aim 2 will evaluate in the established Renca tumor model, the IGIF antitumor efficacies by using different approaches, including IGIF-transduced Renca cells, recombinant IGIF protein as well as in vivo skin transfection of IGIF cDNA by a gene gun. Once Renca tumor regression by IGIF is demonstrated, tumor-infiltrating immune cells will be characterized, and the effector cells determined.
Specific Aim 3 will examine the role of endogenous IGIF in tumor rejection as well as explore the functional relationship between IGIF and IL-2 using the spontaneous rejecting tumor models. Finally, to evaluate the potential of IGIF as a potent, curative antitumor therapeutic, Specific Aim 4 will examine IGIF antitumor effects in several tumor models that are less responsive to IL-12 immunotherapy.
Specific Aim 4 will also determine potential synergism between IGIF and other immunomodulatory molecules, including IL-2, B7.1 and IL-12, in adjunctive antitumor therapies. New knowledge gained from these studies may eventually increase the spectrum of human cancers curable by immunotherapeutics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
1R29CA075243-01
Application #
2382826
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1997-07-07
Project End
1998-06-30
Budget Start
1997-07-07
Budget End
1998-06-30
Support Year
1
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of South Florida
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
City
Tampa
State
FL
Country
United States
Zip Code
33612
Xu, Qing; Briggs, Jon; Park, Sungman et al. (2005) Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24:5552-60
Burdelya, Lyudmila; Kujawski, Maciej; Niu, Guilian et al. (2005) Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol 174:3925-31
Burdelya, Lyudmila; Catlett-Falcone, Robyn; Levitzki, Alexander et al. (2002) Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Mol Cancer Ther 1:893-9
Niu, Guilian; Bowman, Tammy; Huang, Mei et al. (2002) Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21:7001-10
Niu, Guilian; Wright, Kenneth L; Huang, Mei et al. (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21:2000-8
Niu, G; Shain, K H; Huang, M et al. (2001) Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res 61:3276-80
Shtil, A A; Turner, J G; Dalton, W S et al. (2000) Alternative pathways of cell death to circumvent pleiotropic resistance in myeloma cells: role of cytotoxic T-lymphocytes. Leuk Lymphoma 38:59-70
Tan, J; Yang, N S; Turner, J G et al. (1999) Interleukin-12 cDNA skin transfection potentiates human papillomavirus E6 DNA vaccine-induced antitumor immune response. Cancer Gene Ther 6:331-9
Niu, G; Heller, R; Catlett-Falcone, R et al. (1999) Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 59:5059-63
Seigne, J; Turner, J; Diaz, J et al. (1999) A feasibility study of gene gun mediated immunotherapy for renal cell carcinoma. J Urol 162:1259-63

Showing the most recent 10 out of 12 publications